TD Cowen analyst Tyler Van Buren reiterated a Buy rating on C4 Therapeutics (NASDAQ: CCCC).The analyst comments "C4 has initiated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE